Review

Department of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan, MI 48109, USA

^*Both authors contributed equally

Lindsey Ott^*

Bioengineering Program, University of Kansas, Lawrence, KS 66045, USA

^*Both authors contributed equally

Search for more papers by this author

Kiran Seshareddy

Department of Anatomy & Physiology, Kansas State University, Manhattan, KS 66506, USA

Search for more papers by this author

Mark L Weiss

Department of Anatomy & Physiology, Kansas State University, Manhattan, KS 66506, USA

Search for more papers by this author

Michael S Detamore

† Author for correspondence

Department of Chemical & Petroleum Engineering, University of Kansas, Lawrence, KS 66045, USA.

Search for more papers by this author

Email the corresponding author at detamore@ku.edu

Published Online:22 Dec 2010https://doi.org/10.2217/rme.10.98

View article

Abstract

Multipotent mesenchymal stromal cells (MSCs) hold tremendous promise for tissue engineering and regenerative medicine, yet with so many sources of MSCs, what are the primary criteria for selecting leading candidates? Ideally, the cells will be multipotent, inexpensive, lack donor site morbidity, donor materials should be readily available in large numbers, immunocompatible, politically benign and expandable in vitro for several passages. Bone marrow MSCs do not meet all of these criteria and neither do embryonic stem cells. However, a promising new cell source is emerging in tissue engineering that appears to meet these criteria: MSCs derived from Wharton’s jelly of umbilical cord MSCs. Exposed to appropriate conditions, umbilical cord MSCs can differentiate in vitro along several cell lineages such as the chondrocyte, osteoblast, adipocyte, myocyte, neuronal, pancreatic or hepatocyte lineages. In animal models, umbilical cord MSCs have demonstrated in vivo differentiation ability and promising immunocompatibility with host organs/tissues, even in xenotransplantation. In this article, we address their cellular characteristics, multipotent differentiation ability and potential for tissue engineering with an emphasis on musculoskeletal tissue engineering.

Keywords:

Bibliography

1 Vats A, Bielby RC, Tolley NS, Nerem R, Polak JM: Stem cells. Lancet366(9485),592–602 (2005).
Medline CASGoogle Scholar
2 Brignier AC, Gewirtz AM: Embryonic and adult stem cell therapy. J. Allergy Clin. Immunol.125(2 Suppl. 2),S336–S344 (2010).
MedlineGoogle Scholar
3 Kaufman DS, Hanson ET, Lewis RL et al.: Hematopoietic colony-forming cells derived from human embryonic stem cells. Proc. Natl. Acad. Sci. USA98(19),10716–10721 (2001).
Medline CASGoogle Scholar
4 Assady S, Maor G, Amit M, Itskovitz-Eldor J, Skorecki KL, Tzukerman M: Insulin production by human embryonic stem cells. Diabetes50(8),1691–1697 (2001).
Medline CASGoogle Scholar
5 Green H, Easley K, Iuchi S: Marker succession during the development of keratinocytes from cultured human embryonic stem cells. Proc. Natl Acad. Sci. USA100(26),15625–15630 (2003).
Medline CASGoogle Scholar
6 Blum B, Benvenisty N: The tumorigenicity of human embryonic stem cells. Adv. Cancer Res.100,133–158 (2008).
MedlineGoogle Scholar
7 Cai J, Li W, Su H et al.: Generation of human induced pluripotent stem cells from umbilical cord matrix and amniotic membrane mesenchymal cells. J. Biol. Chem.285(15),11227–11234 (2010).
Medline CASGoogle Scholar
8 Okita K, Ichisaka T, Yamanaka S: Generation of germline-competent induced pluripotent stem cells. Nature448(7151),313–317 (2007).
Medline CASGoogle Scholar
9 Yu J, Vodyanik MA, Smuga-Otto K et al.: Induced pluripotent stem cell lines derived from human somatic cells. Science318(5858),1917–1920 (2007).
Medline CASGoogle Scholar
10 Maherali N, Sridharan R, Xie W et al.: Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell1(1),55–70 (2007).
Medline CASGoogle Scholar
11 Wernig M, Meissner A, Foreman R et al.: In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature448(7151),318–324 (2007).
Medline CASGoogle Scholar
12 Di Nicola M, Carlo-Stella C, Magni M et al.: Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood99(10),3838–3843 (2002).
Medline CASGoogle Scholar
13 Bartholomew A, Sturgeon C, Siatskas M et al.: Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol.30(1),42–48 (2002).
MedlineGoogle Scholar
14 Kode JA, Mukherjee S, Joglekar MV, Hardikar AA: Mesenchymal stem cells: immunobiology and role in immunomodulation and tissue regeneration. Cytotherapy11(4),377–391 (2009).
Medline CASGoogle Scholar
15 Quarto R, Mastrogiacomo M, Cancedda R et al.: Repair of large bone defects with the use of autologous bone marrow stromal cells. N. Engl. J. Med.344(5),385–386 (2001).
Medline CASGoogle Scholar
16 Marcacci M, Kon E, Moukhachev V et al.: Stem cells associated with macroporous bioceramics for long bone repair: 6- to 7-year outcome of a pilot clinical study. Tissue Eng.13(5),947–955 (2007).
Medline CASGoogle Scholar
17 Mueller SM, Glowacki J: Age-related decline in the osteogenic potential of human bone marrow cells cultured in three-dimensional collagen sponges. J. Cell Biochem.82(4),583–590 (2001).
Medline CASGoogle Scholar
18 Lee SY, Miwa M, Sakai Y et al.: In vitro multipotentiality and characterization of human unfractured traumatic hemarthrosis-derived progenitor cells: a potential cell source for tissue repair. J. Cell Physiol.210(3),561–566 (2007).
Medline CASGoogle Scholar
19 Schaffler A, Buchler C: Concise review: adipose tissue-derived stromal cells – basic and clinical implications for novel cell-based therapies. Stem Cells25(4),818–827 (2007).
MedlineGoogle Scholar
20 Gimble JM, Katz AJ, Bunnell BA: Adipose-derived stem cells for regenerative medicine. Circ. Res.100(9),1249–1260 (2007).
Medline CASGoogle Scholar
21 Zuk PA, Zhu M, Ashjian P et al.: Human adipose tissue is a source of multipotent stem cells. Mol. Biol. Cell13(12),4279–4295 (2002).
Medline CASGoogle Scholar
22 Nakashima M, Reddi AH: The application of bone morphogenetic proteins to dental tissue engineering. Nat. Biotechnol.21(9),1025–1032 (2003).
Medline CASGoogle Scholar
23 Sloan AJ, Waddington RJ: Dental pulp stem cells: what, where, how? Int. J. Paediatr. Dent.19(1),61–70 (2009).
MedlineGoogle Scholar
24 Gronthos S, Brahim J, Li W et al.: Stem cell properties of human dental pulp stem cells. J. Dent. Res.81(8),531–535 (2002).
Medline CASGoogle Scholar
25 Tuan RS, Boland G, Tuli R: Adult mesenchymal stem cells and cell-based tissue engineering. Arthritis Res. Ther.5(1),32–45 (2003).
Medline CASGoogle Scholar
26 Choumerianou DM, Dimitriou H, Kalmanti M: Stem cells: promises versus limitations. Tissue Eng. Part B Rev.14(1),53–60 (2008).
Medline CASGoogle Scholar
27 Secco M, Zucconi E, Vieira NM et al.: Mesenchymal stem cells from umbilical cord: do not discard the cord! Neuromuscul. Disord.18(1),17–18 (2008).
MedlineGoogle Scholar
28 Prockop DJ: Marrow stromal cells as stem cells for nonhematopoietic tissues. Science276(5309),71–74 (1997).
Medline CASGoogle Scholar
29 Childs R, Chernoff A, Contentin N et al.: Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N. Engl. J. Med.343(11),750–758 (2000).
Medline CASGoogle Scholar
30 Jones EA, English A, Henshaw K et al.: Enumeration and phenotypic characterization of synovial fluid multipotential mesenchymal progenitor cells in inflammatory and degenerative arthritis. Arthritis Rheum.50(3),817–827 (2004).
MedlineGoogle Scholar
31 Huelsken J, Vogel R, Erdmann B, Cotsarelis G, Birchmeier W: β-catenin controls hair follicle morphogenesis and stem cell differentiation in the skin. Cell105(4),533–545 (2001).
Medline CASGoogle Scholar
32 Seale P, Asakura A, Rudnicki MA: The potential of muscle stem cells. Dev. Cell1(3),333–342 (2001).
Medline CASGoogle Scholar
33 Weiss ML, Medicetty S, Bledsoe AR et al.: Human umbilical cord matrix stem cells: preliminary characterization and effect of transplantation in a rodent model of Parkinson’s disease. Stem Cells24(3),781–792 (2006).
Medline CASGoogle Scholar
34 Guilak F, Awad HA, Fermor B, Leddy HA, Gimble JM: Adipose-derived adult stem cells for cartilage tissue engineering. Biorheology41(3–4),389–399 (2004).
Medline CASGoogle Scholar
35 Dominici M, Le Blanc K, Mueller I et al.: Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy8(4),315–317 (2006).
Medline CASGoogle Scholar
36 Karahuseyinoglu S, Cinar O, Kilic E et al.: Biology of stem cells in human umbilical cord stroma: in situ and in vitro surveys. Stem Cells25(2),319–331 (2007).
Medline CASGoogle Scholar
37 Troyer DL, Weiss ML: Wharton’s jelly-derived cells are a primitive stromal cell population. Stem Cells26(3),591–599 (2008).
MedlineGoogle Scholar
38 Campard D, Lysy PA, Najimi M, Sokal EM: Native umbilical cord matrix stem cells express hepatic markers and differentiate into hepatocyte-like cells. Gastroenterology134(3),833–848 (2008).
Medline CASGoogle Scholar
39 Weiss ML, Troyer DL: Stem cells in the umbilical cord. Stem Cell Rev.2(2),155–162 (2006).
Medline CASGoogle Scholar
40 Can A, Karahuseyinoglu S: Concise review: human umbilical cord stroma with regard to the source of fetus-derived stem cells. Stem Cells25(11),2886–2895 (2007).
MedlineGoogle Scholar
41 Ciavarella S, Dammacco F, De Matteo M, Loverro G, Silvestris F: Umbilical cord mesenchymal stem cells: role of regulatory genes in their differentiation to osteoblasts. Stem Cells Dev.18(8),1211–1220 (2009).
Medline CASGoogle Scholar
42 Cho PS, Messina DJ, Hirsh EL et al.: Immunogenicity of umbilical cord tissue derived cells. Blood111(1),430–438 (2008).
Medline CASGoogle Scholar
43 Ennis J, Götherström C, Le Blanc K, Davies JE: In vitro immunologic properties of human umbilical cord perivascular cells. Cytotherapy10(2),174–181 (2008).
Medline CASGoogle Scholar
44 Sarugaser R, Ennis J, Stanford WL, Davies JE: Isolation, propagation, and characterization of human umbilical cord perivascular cells (HUCPVCs). Methods Mol. Biol.482,269–279 (2009).
Medline CASGoogle Scholar
45 Hadidian Z, Pirie NW: The preparation and some properties of hyaluronic acid from human umbilical cord. Biochem. J.42(2),260–265 (1948).
Medline CASGoogle Scholar
46 Bowles HE, McKee RD: Ruptures of the umbilical cord with a case of intrapartum rupture or all three vessels. Calif. Med.70(5),422 (1949).
Medline CASGoogle Scholar
47 Moretti P, Hatlapatka T, Marten D et al.: Mesenchymal stromal cells derived from human umbilical cord tissues: primitive cells with potential for clinical and tissue engineering applications. Adv. Biochem. Eng. Biotechnol.123,29–54 (2009).
Google Scholar
48 Mitchell KE, Weiss ML, Mitchell BM et al.: Matrix cells from Wharton’s jelly form neurons and glia. Stem Cells21(1),50–60 (2003).
Medline CASGoogle Scholar
49 Kadner A, Hoerstrup SP, Tracy J et al.: Human umbilical cord cells: a new cell source for cardiovascular tissue engineering. Ann. Thorac. Surg.74(4),S1422–S1428 (2002).
MedlineGoogle Scholar
50 Chao KC, Chao KF, Fu YS, Liu SH: Islet-like clusters derived from mesenchymal stem cells in Wharton’s Jelly of the human umbilical cord for transplantation to control Type 1 diabetes. PLoS ONE3(1),e1451 (2008).
MedlineGoogle Scholar
51 Fong CY, Richards M, Manasi N, Biswas A, Bongso A: Comparative growth behaviour and characterization of stem cells from human Wharton’s jelly. Reprod. Biomed. Online15(6),708–718 (2007).
Medline CASGoogle Scholar
52 Jomura S, Uy M, Mitchell K, Dallasen R, Bode CJ, Xu Y: Potential treatment of cerebral global ischemia with Oct-4⁺ umbilical cord matrix cells. Stem Cells25(1),98–106 (2007).
Medline CASGoogle Scholar
53 Lund RD, Wang S, Lu B et al.: Cells isolated from umbilical cord tissue rescue photoreceptors and visual functions in a rodent model of retinal disease. Stem Cells25(3),602–611 (2007).
Medline CASGoogle Scholar
54 Kadner A, Zund G, Maurus C et al.: Human umbilical cord cells for cardiovascular tissue engineering: a comparative study. Eur. J. Cardiothorac. Surg.25(4),635–641 (2004).
MedlineGoogle Scholar
55 Sodian R, Lueders C, Kraemer L et al.: Tissue engineering of autologous human heart valves using cryopreserved vascular umbilical cord cells. Ann. Thorac. Surg.81(6),2207–2216 (2006).
MedlineGoogle Scholar
56 Schmidt D, Mol A, Neuenschwander S et al.: Living patches engineered from human umbilical cord derived fibroblasts and endothelial progenitor cells. Eur. J. Cardiothorac. Surg.27(5),795–800 (2005).
MedlineGoogle Scholar
57 Schmidt D, Mol A, Odermatt B et al.: Engineering of biologically active living heart valve leaflets using human umbilical cord-derived progenitor cells. Tissue Eng.12(11),3223–3232 (2006).
Medline CASGoogle Scholar
58 Schmidt D, Asmis LM, Odermatt B et al.: Engineered living blood vessels: functional endothelia generated from human umbilical cord-derived progenitors. Ann. Thorac. Surg.82(4),1465–1471; discussion 1471 (2006).
MedlineGoogle Scholar
59 Wang L, Seshareddy K, Weiss ML, Detamore MS: Effect of initial seeding density on human umbilical cord mesenchymal stromal cells for fibrocartilage tissue engineering. Tissue Eng. Part A15(5),1009–1017 (2009).
Medline CASGoogle Scholar
60 Bailey MM, Wang L, Bode CJ et al.: A comparison of human umbilical cord matrix stem cells and temporomandibular joint condylar chondrocytes for tissue engineering temporomandibular joint condylar cartilage. Tissue Eng.13(8),2003–2010 (2007).
Medline CASGoogle Scholar
61 Diao Y, Ma Q, Cui F, Zhong Y: Human umbilical cord mesenchymal stem cells: osteogenesis in vivo as seed cells for bone tissue engineering. J. Biomed. Mater. Res. A91(1),123–131 (2008).
Google Scholar
62 Heifetz SA: The umbilical cord: obstetrically important lesions. Clin. Obstet. Gynecol.39(3),571–587 (1996).
Medline CASGoogle Scholar
63 Hill LM, Kislak S, Runco C: An ultrasonic view of the umbilical cord. Obstet. Gynecol. Surv.42(2),82–88 (1987).
Medline CASGoogle Scholar
64 Sarugaser R, Lickorish D, Baksh D, Hosseini MM, Davies JE: Human umbilical cord perivascular (HUCPV) cells: a source of mesenchymal progenitors. Stem Cells23(2),220–229 (2005).
MedlineGoogle Scholar
65 Wang HS, Hung SC, Peng ST et al.: Mesenchymal stem cells in the Wharton’s jelly of the human umbilical cord. Stem Cells22(7),1330–1337 (2004).
MedlineGoogle Scholar
66 Fong CY, Subramanian A, Biswas A et al.: Derivation efficiency, cell proliferation, freeze-thaw survival, stem-cell properties and differentiation of human Wharton’s jelly stem cells. Reprod. Biomed. Online21(3),391–401 (2010).
MedlineGoogle Scholar
67 Nanaev AK, Kohnen G, Milovanov AP, Domogatsky SP, Kaufmann P: Stromal differentiation and architecture of the human umbilical cord. Placenta18(1),53–64 (1997).
Medline CASGoogle Scholar
68 Kobayashi K, Kubota T, Aso T: Study on myofibroblast differentiation in the stromal cells of Wharton’s jelly: expression and localization of α-smooth muscle actin. Early Hum. Dev.51(3),223–233 (1998).
Medline CASGoogle Scholar
69 Bongso A, Fong CY, Gauthaman K: Taking stem cells to the clinic: major challenges. J. Cell Biochem.105(6),1352–1360 (2008).
Medline CASGoogle Scholar
70 Majore I, Moretti P, Stahl F, Hass R, Kasper C: Growth and differentiation properties of mesenchymal stromal cell populations derived from whole human umbilical cord. Stem Cell Rev. (2010) (Epub ahead of print).
Google Scholar
71 Lu LL, Liu YJ, Yang SG et al.: Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica91(8),1017–1026 (2006).
Medline CASGoogle Scholar
72 Wu KH, Zhou B, Lu SH et al.: In vitro and in vivo differentiation of human umbilical cord derived stem cells into endothelial cells. J. Cell Biochem.100(3),608–616 (2007).
Medline CASGoogle Scholar
73 Hoerstrup SP, Kadner A, Breymann C et al.: Living, autologous pulmonary artery conduits tissue engineered from human umbilical cord cells. Ann. Thorac. Surg.74(1),46–52; discussion 52 (2002).
MedlineGoogle Scholar
74 Eblenkamp M, Aigner J, Hintermair J et al.: [Umbilical cord stromal cells (UCSC). Cells featuring osteogenic differentiation potential]. Orthopade33(12),1338–1345 (2004).
Medline CASGoogle Scholar
75 Carlin R, Davis D, Weiss M et al.: Expression of early transcription factors Oct4, Sox2 and Nanog by porcine umbilical cord (PUC) matrix cells. Reprod. Biol. Endocrinol.4(1),8 (2006).
MedlineGoogle Scholar
76 Wu KH, Zhou B, Yu CT et al.: Therapeutic potential of human umbilical cord derived stem cells in a rat myocardial infarction model. Ann. Thorac. Surg.83(4),1491–1498 (2007).
MedlineGoogle Scholar
77 Jo CH, Kim OS, Park EY et al.: Fetal mesenchymal stem cells derived from human umbilical cord sustain primitive characteristics during extensive expansion. Cell Tissue Res.334(3),423–433 (2008).
MedlineGoogle Scholar
78 Zhang P, Luo X, Wang H: Clinical transplantation of a tissue-engineered airway. Lancet373(9665),718; author reply 718–719 (2009).
MedlineGoogle Scholar
79 Fong CY, Chak LL, Biswas A et al.: Human Wharton’s jelly stem cells have unique transcriptome profiles compared to human embryonic stem cells and other mesenchymal stem cells. Stem Cell Rev. (2010) (Epub ahead of print).
Google Scholar
80 Liedtke S, Stephan M, Kogler G: Oct4 expression revisited: potential pitfalls for data misinterpretation in stem cell research. Biol. Chem.389(7),845–850 (2008).
Medline CASGoogle Scholar
81 Méndez-Ferrer S, Michurina TV, Ferraro F et al.: Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature466(7308),829–834 (2010).
Medline CASGoogle Scholar
82 Baksh D, Yao R, Tuan RS: Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. Stem Cells25(6),1384–1392 (2007).
Medline CASGoogle Scholar
83 Kita K, Gauglitz GG, Phan TT, Herndon DN, Jeschke MG: Isolation and characterization of mesenchymal stem cells from the sub-amniotic human umbilical cord lining membrane. Stem Cells Dev.19(4),491–502 (2010).
Medline CASGoogle Scholar
84 Anzalone R, Lo Iacono M, Corrao S et al.: New emerging potentials for human Wharton’s jelly mesenchymal stem cells: immunological features and hepatocyte-like differentiative capacity. Stem Cells Dev.19(4),423–438 (2010).
Medline CASGoogle Scholar
85 Fan CG, Zhang QJ, Zhou JR: Therapeutic potentials of mesenchymal stem cells derived from human umbilical cord. Stem Cell Rev. (2010) (Epub ahead of print).
Google Scholar
86 Gao J, Yao JQ, Caplan AI: Stem cells for tissue engineering of articular cartilage. Proc. Inst. Mech. Eng.221(5),441–450 (2007).
Medline CASGoogle Scholar
87 Darling EM, Athanasiou KA: Rapid phenotypic changes in passaged articular chondrocyte subpopulations. J. Orthop. Res.23(2),425–432 (2005).
Medline CASGoogle Scholar
88 Johnstone B, Hering TM, Caplan AI, Goldberg VM, Yoo JU: In vitro chondrogenesis of bone marrow-derived mesenchymal progenitor cells. Exp. Cell Res.238(1),265–272 (1998).
Medline CASGoogle Scholar
89 Mackay AM, Beck SC, Murphy JM, Barry FP, Chichester CO, Pittenger MF: Chondrogenic differentiation of cultured human mesenchymal stem cells from marrow. Tissue Eng.4(4),415–428 (1998).
Medline CASGoogle Scholar
90 Im GI, Jung NH, Tae SK: Chondrogenic differentiation of mesenchymal stem cells isolated from patients in late adulthood: the optimal conditions of growth factors. Tissue Eng.12(3),527–536 (2006).
Medline CASGoogle Scholar
91 Spagnoli A, Longobardi L, O’Rear L: Cartilage disorders: potential therapeutic use of mesenchymal stem cells. Endocr. Dev.9,17–30 (2005).
Medline CASGoogle Scholar
92 Longobardi L, O’Rear L, Aakula S et al.: Effect of IGF-I in the chondrogenesis of bone marrow mesenchymal stem cells in the presence or absence of TGF-β signaling. J. Bone Miner. Res.21(4),626–636 (2006).
Medline CASGoogle Scholar
93 Wang L, Detamore MS: Insulin-like growth factor-I improves chondrogenesis of predifferentiated human umbilical cord mesenchymal stromal cells. J. Orthop. Res.27(8),1109–1115 (2009).
Medline CASGoogle Scholar
94 Naughton BA: Cells isolated from Wharton’s jelly of the human umbilical cord develop a cartilage phenotype when treated with TGF-β in vitro.FASEB J.11,A19 (Abstr. No. 108) (1997).
MedlineGoogle Scholar
95 Barry F, Boynton RE, Liu B, Murphy JM: Chondrogenic differentiation of mesenchymal stem cells from bone marrow: differentiation-dependent gene expression of matrix components. Exp. Cell Res.268(2),189–200 (2001).
Medline CASGoogle Scholar
96 Pittenger MF, Mackay AM, Beck SC et al.: Multilineage potential of adult human mesenchymal stem cells. Science284(5411),143–147 (1999).
Medline CASGoogle Scholar
97 Wang L, Tran I, Seshareddy K, Weiss ML, Detamore MS: A comparison of human bone marrow-derived mesenchymal stem cells and human umbilical cord-derived mesenchymal stromal cells for cartilage tissue engineering. Tissue Eng. Part A15(8),2259–2266 (2009).
Medline CASGoogle Scholar
98 Motoki DS, Mulliken JB: The healing of bone and cartilage. Clin. Plast. Surg.17(3),527–544 (1990).
Medline CASGoogle Scholar
99 Habal MB: Bone repair by regeneration. Clin. Plast. Surg.23(1),93–101 (1996).
Medline CASGoogle Scholar
100 Salgado AJ, Coutinho OP, Reis RL: Bone tissue engineering: state of the art and future trends. Macromol. Biosci.4(8),743–765 (2004).
Medline CASGoogle Scholar
101 Martin-Rendon E, Sweeney D, Lu F, Girdlestone J, Navarrete C, Watt SM: 5-azacytidine-treated human mesenchymal stem/progenitor cells derived from umbilical cord, cord blood and bone marrow do not generate cardiomyocytes in vitro at high frequencies. Vox Sang.95(2),137–148 (2008).
Medline CASGoogle Scholar
102 Hou T, Xu J, Wu X et al.: Umbilical cord Wharton’s Jelly: a new potential cell source of mesenchymal stromal cells for bone tissue engineering. Tissue Eng. Part A15(9),2325–2334 (2009).
Medline CASGoogle Scholar
103 Xu HH, Zhao L, Detamore MS, Takagi S, Chow LC: Umbilical cord stem cell seeding on fast-resorbable calcium phosphate bone cement. Tissue Eng. Part A16(9),2743–2753 (2010).
Medline CASGoogle Scholar
104 Honsawek S, Dhitiseith D, Phupong V: Effects of demineralized bone matrix on proliferation and osteogenic differentiation of mesenchymal stem cells from human umbilical cord. J. Med. Assoc. Thai.89(Suppl. 3),S189–S195 (2006).
MedlineGoogle Scholar
105 Zhang ZY, Teoh SH, Chong MS et al.: Superior osteogenic capacity for bone tissue engineering of fetal compared to perinatal and adult mesenchymal stem cells. Stem Cells27(1),126–131 (2009).
MedlineGoogle Scholar
106 Wang L, Singh M, Bonewald LF, Detamore MS: Signalling strategies for osteogenic differentiation of human umbilical cord mesenchymal stromal cells for 3D bone tissue engineering. J. Tissue Eng. Regen. Med.3(5),398–404 (2009).
Medline CASGoogle Scholar
107 Gauthaman K, Venugopal JR, Yee FC et al.: Osteogenic differentiation of human Wharton’s jelly stem cells on nanofibrous substrates in vitro. Tissue Eng. Part A (2010) (Epub ahead of print).
MedlineGoogle Scholar
108 Penolazzi L, Tavanti E, Vecchiatini R et al.: Encapsulation of mesenchymal stem cells from Wharton’s jelly in alginate microbeads. Tissue Eng. Part C Methods16(1),141–155 (2010).
Medline CASGoogle Scholar
109 Zhao L, Weir MD, Xu HH: An injectable calcium phosphate–alginate hydrogel–umbilical cord mesenchymal stem cell paste for bone tissue engineering. Biomaterials31(25),6502–6510 (2010).
Medline CASGoogle Scholar
110 Wang L, Dormer NH, Bonewald LF, Detamore MS: Osteogenic differentiation of human umbilical cord mesenchymal stromal cells in polyglycolic acid scaffolds. Tissue Eng. Part A16(6),1937–1948 (2010).
Medline CASGoogle Scholar
111 Wang L, Detamore MS: Human umbilical cord mesenchymal stromal cells in a sandwich approach for osteochondral tissue engineering. J. Tissue Eng. Regen. Med. (2010) (Epub ahead of print).
Google Scholar
112 Dormer NH, Singh M, Wang L, Berkland CJ, Detamore MS: Osteochondral interface tissue engineering using macroscopic gradients of bioactive signals. Ann. Biomed. Eng.38(6),2167–2182 (2010).
MedlineGoogle Scholar
113 Conconi MT, Burra P, Di Liddo R et al.: CD105⁺ cells from Wharton’s jelly show in vitro and in vivo myogenic differentiative potential. Int. J. Mol. Med.18(6),1089–1096 (2006).
Medline CASGoogle Scholar
114 Kocaefe C, Balci D, Hayta BB, Can A: Reprogramming of human umbilical cord stromal mesenchymal stem cells for myogenic differentiation and muscle repair. Stem Cell Rev.6(4),512–522 (2010).
Google Scholar
115 Vieira NM, Zucconi E, Bueno CR Jr et al.: Human multipotent mesenchymal stromal cells from distinct sources show different in vivo potential to differentiate into muscle cells when injected in dystrophic mice. Stem Cell Rev.6(4),560–566 (2010).
CASGoogle Scholar
116 Patrick CW Jr: Tissue engineering strategies for adipose tissue repair. Anat. Rec.263(4),361–366 (2001).
Medline CASGoogle Scholar
117 Gomillion CT, Burg KJ: Stem cells and adipose tissue engineering. Biomaterials27(36),6052–6063 (2006).
Medline CASGoogle Scholar
118 Turner NJ, Jones HS, Davies JE, Canfield AE: Cyclic stretch-induced TGFb1/Smad signaling inhibits adipogenesis in umbilical cord progenitor cells. Biochem. Biophys. Res. Commun.377(4),1147–1151 (2008).
Medline CASGoogle Scholar
119 Karahuseyinoglu S, Kocaefe C, Balci D, Erdemli E, Can A: Functional structure of adipocytes differentiated from human umbilical cord stroma-derived stem cells. Stem Cells26(3),682–691 (2008).
MedlineGoogle Scholar
120 Breymann C, Schmidt D, Hoerstrup SP: Umbilical cord cells as a source of cardiovascular tissue engineering. Stem Cell Rev.2(2),87–92 (2006).
MedlineGoogle Scholar
121 Schmidt D, Hoerstrup SP: Tissue engineered heart valves based on human cells. Swiss Med. Wkly137(Suppl. 155),80S–85S (2007).
MedlineGoogle Scholar
122 Martin JA, Hamilton BE, Sutton PD et al.: Births: final data for 2005. Natl Vital Stat. Rep.56(6),1–103 (2007).
MedlineGoogle Scholar
123 Weiss ML, Anderson C, Medicetty S et al.: Immune properties of human umbilical cord Wharton’s jelly-derived cells. Stem Cells26(11),2865–2874 (2008).
Medline CASGoogle Scholar
124 Drukker M: Immunogenicity of human embryonic stem cells: can we achieve tolerance? Springer Semin. Immunopathol.26(1–2),201–213 (2004).
MedlineGoogle Scholar
125 Drukker M, Benvenisty N: The immunogenicity of human embryonic stem-derived cells. Trends Biotechnol.22(3),136–141 (2004).
Medline CASGoogle Scholar
126 Najar M, Raicevic G, Boufker HI et al.: Adipose-tissue-derived and Wharton’s jelly-derived mesenchymal stromal cells suppress lymphocyte responses by secreting leukemia inhibitory factor. Tissue Eng. Part A16(11),3537–3546 (2010).
Medline CASGoogle Scholar
127 Najar M, Raicevic G, Boufker HI et al.: Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: combined comparison of adipose tissue, Wharton’s Jelly and bone marrow sources. Cell Immunol.264(2),171–179 (2010).
Medline CASGoogle Scholar
128 Selmani Z, Naji A, Zidi I et al.: Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4⁺CD25highFOXP3⁺ regulatory T cells. Stem Cells26(1),212–222 (2008).
Medline CASGoogle Scholar
129 Patel SA, Sherman L, Munoz J, Rameshwar P: Immunological properties of mesenchymal stem cells and clinical implications. Arch. Immunol. Ther. Exp. (Warsz) 56(1),1–8 (2008).
Medline CASGoogle Scholar
130 Weiss ML, Mitchell KE, Hix JE et al.: Transplantation of porcine umbilical cord matrix cells into the rat brain. Exp. Neurol.182(2),288–299 (2003).
Medline CASGoogle Scholar
131 Chen X, McClurg A, Zhou GQ, McCaigue M, Armstrong MA, Li G: Chondrogenic differentiation alters the immunosuppressive property of bone marrow-derived mesenchymal stem cells and the effect is partially due to the upregulated expression of B7 molecules. Stem Cells25(2),364–370 (2007).
MedlineGoogle Scholar
132 Mannello F, Tonti GA: Concise review: no breakthroughs for human mesenchymal and embryonic stem cell culture: conditioned medium, feeder layer, or feeder-free; medium with fetal calf serum, human serum, or enriched plasma; serum-free, serum replacement nonconditioned medium, or ad hoc formula? All that glitters is not gold! Stem Cells25(7),1603–1609 (2007).
Medline CASGoogle Scholar
133 Galban CJ, Locke BR: Analysis of cell growth kinetics and substrate diffusion in a polymer scaffold. Biotechnol. Bioeng.65(2),121–132 (1999).
Medline CASGoogle Scholar
134 Seshareddy K, Troyer D, Weiss ML: Method to isolate mesenchymal-like cells from Wharton’s Jelly of umbilical cord. Methods Cell Biol.86,101–119 (2008).
Medline CASGoogle Scholar
135 Kim JW, Kim SY, Park SY et al.: Mesenchymal progenitor cells in the human umbilical cord. Ann. Hematol.83(12),733–738 (2004).
Medline CASGoogle Scholar

Vol. 6, No. 1

Metrics

Downloaded 311 times

History

Published online 22 December 2010

Published in print January 2011

Information

Keywords

Financial & competing interests disclosure

The authors gratefully acknowledge support from the Arthritis Foundation, both from the national organization and from the Kansas Chapter. They further acknowledge support from the NSF CAREER Award (MS Detamore). ML Weiss is supported by NIH grant NS-34160, and a KSU Targeted Excellence grant. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download

Musculoskeletal tissue engineering with human umbilical cord mesenchymal stromal cells

Abstract

Bibliography